近年来,我国创新药产业快速发展,成果显著,吸引了多家海外药企争相合作与采购,标志着中国创新药正作为新兴优势产业登上全球舞台。近期,创新药板块表现抢眼,恒生港股通创新药指数年内涨幅超60%,领跑市场。6月30日,恒生港股通创新药指数宣布修订编制方案,明确剔除CXO公司,更精准地聚焦创新药核心公司,进而能够更好地反映创新药产业发展趋势。在此背景下,面对创新药这一“黄金赛道”,普通投资者该如何把握机遇?...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.